Arexvy associated with reductions in certain RSV-related risks including heart attack, stroke and severe flare-ups of COPD and asthma

GSK has recently announced their new effectiveness data for its adjuvanted recombinant RSV vaccine at RSVVW’26, the 9th Conference of the Respiratory Syncytial Virus Foundation in Rome, Italy. GSK is presenting 19 abstracts at the congress and supporting a further 3, reflecting GSK’s leadership in research and prevention of RSV.

In addition, hospitalisation places a significant burden on patients and health systems, particularly in winter months. A retrospective cohort study was undertaken in the US with the primary objective to assess the effectiveness of GSK’s RSV vaccine in helping to prevent RSV-related hospitalisation in adults aged ≥60 years. It included over 2.5 million people, of which 520,440 were vaccinated individuals who were exact matched 1:4 to 2,081,760 unvaccinated individuals.

Note that while observational research cannot demonstrate a causal association between RSV vaccination and reduced RSV-related risks, these findings add to a growing body of evidence of observed risk reductions in cardiovascular and respiratory underlying diseases. GSK’s RSV vaccine is indicated for the prevention of RSV-lower respiratory tract disease.

Deepak L. Bhatt, MD, MPH, MBA, Director of Mount Sinai Fuster Heart Hospital and the Dr. Valentin Fuster Professor of Cardiovascular Medicine at the Icahn School of Medicine at Mount Sinai in New York, said: “In the real-world data being presented at RSVVW’26, it is observed that RSV vaccination could help reduce the risk of certain serious RSV-related outcomes, potentially including major adverse cardiovascular events such as heart attack and stroke, as well as severe flare-ups of COPD and asthma. These new data are a significant step in our understanding of how to help prevent such RSV-related health outcomes. I look forward to more data investigating this association further.”

Christian Felter, GSK Global Medical Lead, RSV, said: “These data underscore the value of our RSV vaccine in its observed association with helping to prevent RSV-related hospitalisation and reducing the risk of acute events of certain chronic conditions associated with this potentially serious disease. We are proud of our contribution at the forefront of generating innovative research in RSV to inform the clinical community and improve outcomes for patients.”

---

---

Related Topics and Keywords

arexvy, asthma, GSK, GSK’s Arexvy, heart attack, respiratory syncytial virus (RSV), rsv